The U.S. Food and Drug Administration (FDA) has asked drug companies to remove warnings about the potential for suicidal thoughts from the labels of popular weight-loss and blood sugar-control drugs, including Novo Nordisk’s Wegovi and Eli Lilly’s Zipound. The decision also includes Saxenda, an older version of the weight-loss drug produced by Novo Nordisk, following a comprehensive review by the administration that found no evidence linking the use...